#USA #Sarasota #Lakewood-Amedex #Nu-3 #LABT

Lakewood-Amedex Biotherapeutics: Transformational Progress in Nu-3 Development

Lakewood-Amedex Biotherapeutics Inc., a clinical-stage biotechnology company, recently highlighted a pivotal moment in its journey, particularly regarding its innovative antimicrobial product, Nu-3. In a letter addressed to shareholders, CEO Dr. Kelvin Cooper underscored the company's recent achievements and the significant steps they are taking to advance Nu-3 into clinical trials. This development is particularly crucial considering the increasing global issue of antimicrobial resistance, which has rendered traditional antibiotics less effective for infections, particularly in diabetic patients.

Recent Achievements

As of recently, Lakewood-Amedex successfully transitioned to being publicly traded on the Nasdaq Capital Market under the ticker symbol LABT. This is a substantial milestone that not only enhances the company's visibility but also improves access to capital. Accompanying this listing, the company completed a private placement that raised approximately $7.5 million, significantly bolstering their financial foundation as they push forward with clinical research.

The company is focusing on Nu-3, a topical gel designed to treat infected diabetic foot ulcers (iDFUs), which are common complications for individuals with diabetes. Positive preclinical safety and efficacy findings have emerged, showing low systemic exposure and confirming that Nu-3 supports the natural healing process of wounds, pivotal for diabetes patients. These findings have enabled the selection of various strengths for testing in upcoming clinical trials, a promising indication of Nu-3's potential.

Clinical Trial Preparation

The next major milestone for Lakewood-Amedex will be the initiation of the Phase 2a clinical trial for Nu-3. Renowned expert Dr. David G. Armstrong will serve as the Study Chair and Scientific Advisor, providing the program with invaluable expertise in diabetic foot care and wound healing. The leadership team's qualifications are expected to drive the research forward efficiently and capably.

In addition, the strict adherence to project timelines and effective regulatory strategies is paramount as the company prepares to collect clinical evidence that could validate Nu-3 as a groundbreaking treatment option not just for diabetic foot ulcers but potentially for a broader range of infections linked to antimicrobial resistance.

Expanding the Intellectual Property Portfolio

To safeguard its innovative technology, Lakewood-Amedex has been proactive in expanding its intellectual property portfolio. Presently, they hold 72 granted patents and have 29 pending applications worldwide. This robust framework is critical for securing the future of their proprietary Bisphosphocin® technology, which introduces a novel method of treating bacterial infections, increasing their marketability and potential commercial success.

Financial Restructuring and Future Outlook

As part of their strategic growth, the company took significant steps to strengthen its financial position through a streamlining process, which involved converting preferred shares into common stock and improving liquidity. They have plans to increase the number of authorized common shares to 100 million, along with a potential reverse split strategy to maintain Nasdaq listing requirements, thereby positioning themselves for continued growth and stability.

Dr. Cooper expressed great optimism for the company's trajectory, emphasizing the importance of accelerating Nu-3 through its clinical development phases. He noted that successful clinical outcomes could not only pave the way for much-needed treatments for patients but also serve as a testament to the viability of their entire Bisphosphocin® platform.

In conclusion, Lakewood-Amedex Biotherapeutics stands at a crucial juncture, armed with a strong foundation, extensive expertise, and promising data concerning Nu-3. The upcoming clinical trials will be pivotal in demonstrating the efficacy of this innovative treatment and helping to address a significant healthcare challenge posed by antimicrobial-resistant infections. As they continue this journey, the commitment from the executive team, backed by both clinical and public support, will be vital to the company's future successes.